Clinical trial
Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor…
NCT02193191 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT02193191 |
|---|---|
| Title | Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease |
| Official title | Safety and Efficacy Trial of Escalation of Plerixafor for Mobilization of CD34+ Hematopoietic Progenitor Cells and Evaluation of Globin Gene Transfer in Patients With Sickle Cell Disease |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | Sanofi Industry New York Blood Center Weill Medical College of Cornell University Duke University |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Sickle Cell Disease |
| Intervention type | Drug |
| Interventions | Plerixafor |
| Enrollment | 25 |
| Start date | Sep 17, 2014 |
| Primary completion | Mar 27, 2025 |
| Completion | Mar 27, 2025 |
| First posted | Jul 17, 2014 |
| Last update posted | Mar 30, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: